Glycomet

intended to target high blood sugar levels and to support metabolic control in diabetes.

Strengths: 500mg

Medicine details

Alternative names

Glucophage

Therapeutic class

Biguanide Antidiabetic

Pharmacological class

Biguanide

Known off-label uses

polycystic ovary syndrome

Contraindications

renal impairment; diabetic ketoacidosis; severe hepatic impairment

Minor side effects

nausea; diarrhoea; abdominal pain; loss of appetite

Moderate side effects

metallic taste; vitamin B12 deficiency

Serious side effects

lactic acidosis — requires immediate medical attention

Dosage forms

Tablet

Administration route

Oral use

Prescription status

POM

Manufacturer

USV Private Limited

Onset Time

1–2 weeks

Duration

indefinite

Storage instructions

Store at room temperature in a dry place.

Drug interactions

alcohol; iodinated contrast agents; corticosteroids

Age restrictions

Suitable for adults; specific paediatric approval varies by formulation.

Precautions and warnings

discontinue before surgery; regular blood glucose monitoring necessary; risk of vitamin B12 deficiency

Patient summary

intended to target high blood sugar levels and to support metabolic control in diabetes.

Mechanism of action

Reduces hepatic glucose production and improves insulin sensitivity, enhancing peripheral glucose uptake without causing hypoglycaemia.

Pregnancy and breastfeeding

Pregnancy: Insulin is preferred for glucose control during pregnancy. Breastfeeding: Generally considered safe.

Glycomet

intended to target high blood sugar levels and to support metabolic control in diabetes.

Editorial Notes

  • Active ingredient(s): Metformin
  • Listed indication(s): Type 2 Diabetes Mellitus